Pfizer[-]BioNTech said that, if necessary, they expect to be able to ship [!] a new vaccine tailored to the highly contagious variant, first detected in South Africa, in about 100 [?!] days.

BioNTech added Friday it expects to review more data on OMICRON within two weeks to help decide whether the two jab-vaccine should be reworked.
[...]
"A booster dose of an authorized vaccine represents THE ONLY currently available strategy for boosting waning immunity," Moderna said in the statement.

Johnson & Johnson said it too is closely monitoring emerging strains of COVID-19 and is testing the effectiveness of its single-shot jab against the new variant.

Professor Andrew Pollard, director of the Oxford Vaccine Group which developed the AstraZeneca vaccine used overseas, expressed cautious optimism that existing vaccines could be effective at preventing serious disease from the omicron variant.

He said most mutations appear to be in similar [binding] regions as those in other variants.